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1  | INTRODUC TION
Restless legs syndrome (RLS) is a sleep disorder characterized by un‐
comfortable sensations and an intense, often uncontrollable, urge 
to move the legs (Restless Legs Syndrome Foundation, 2018). The 
defining features of RLS include: (a) an urge to move the extremities 
that is accompanied by uncomfortable or unpleasant sensations; (b) 
the sensations are partially or totally relieved by movement; (c) the 
sensations begin or worsen during periods of rest or inactivity; and 
(d) the sensations worsen in the evening (Walters et al., 2003). RLS 
occurs in upwards of 15% of the general population (Ohayon, O'hara, 
& Vitiello, 2012), and the prevalence is substantially higher among 
persons with multiple sclerosis (MS), with estimates as high as 65% 
(Sieminski, Losy, & Partinen, 2015). This presents RLS as one of the 
most common, and potentially burdensome, sleep disorders among 
persons with MS (Braley & Chervin, 2015).
Restless legs syndrome may exacerbate many of the symptoms 
and consequences of MS and could have implications for health‐re‐
lated quality of life (HRQOL). Persons with MS who have RLS re‐
port greater daytime sleepiness, lower sleep quality, worse clinical 
disability (Manconi et al., 2008; Moreira et al., 2008) and greater 
symptoms of depression and fatigue (Aydar, Kurt, Karaer Unaldi, & 
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Abstract
Restless legs syndrome (RLS) is a sleep disorder that may exacerbate many of the 
symptoms and consequences of multiple sclerosis (MS), and may have further implica‐
tions for health‐related quality of life (HRQOL). The present study examined the rela‐
tionships among RLS, symptoms and HRQOL in people with MS. Participants with MS 
(n = 275) completed the Cambridge‐Hopkins Restless Legs Syndrome Questionnaire, 
the International Restless Legs Syndrome Study Group Scale, the Multiple Sclerosis 
Impact Scale, the Pittsburgh Sleep Quality Index, the Fatigue Severity Scale, the 
Hospital Anxiety and Depression Scale and the Patient Determined Disease Steps. 
There were 74 (26.9%) persons with MS who had RLS (MS + RLS). The MS + RLS group 
reported worse physical and psychological HRQOL (p = 0.020 and p = 0.017, respec‐
tively) and greater perceived fatigue (p = 0.006) and anxiety symptoms (p = 0.042) 
than the MS‐only group. Within the MS + RLS group, RLS severity was associated 
with physical (r = 0.43) and psychological (r = 0.46) HRQOL, sleep quality (r = 0.38), 
perceived fatigue (r = 0.28), depression (r = 0.38) and anxiety (r = 0.28). The relation‐
ships between RLS severity and the domains of HRQOL were attenuated when ac‐
counting for fatigue, depression and/or anxiety. Worse RLS severity was associated 
with reduced HRQOL, which was accounted for by fatigue, depression and anxiety.
K E Y W O R D S
anxiety, depression, fatigue, health‐related quality of life, multiple sclerosis, restless legs 
syndrome
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Erkorkmaz, 2011; Moreira et al., 2008) than those with MS who do 
not have RLS. Such co‐occurring consequences of RLS are common 
influences of HRQOL in MS (Benito‐Leon, Morales, Rivera‐Navarro, 
& Mitchell, 2003), yet there is limited evidence regarding the nature 
of the relationship between RLS and HRQOL in MS.
The present study examined the relationship between RLS 
and HRQOL in people with MS. We compared common symptoms 
and consequences associated with MS between groups with and 
without RLS (i.e., MS + RLS and MS groups, respectively) and fur‐
ther examined the association between RLS severity, MS‐related 
outcomes and HRQOL in people with both MS and RLS. This was 
followed by a search for possible intermediary factors in the rela‐
tionship, including disability status, sleep quality, fatigue, depres‐
sion and anxiety in adults with both MS and RLS. We hypothesized 
that those with MS and RLS (i.e., the MS + RLS group) would report 
worse HRQOL, clinical disability, sleep quality, fatigue, depression 
and anxiety than those with MS alone (i.e., the MS group). We 
further hypothesized that the relationship between RLS severity 
and HRQOL in those with MS and RLS might be accounted for by 
the aforementioned co‐occurring consequences of RLS (i.e., sleep 
quality, clinical disability status, fatigue and depression).
2  | MATERIAL S AND METHODS
2.1 | Participants
We recruited a sample of persons with MS through the North 
American Research Committee on Multiple Sclerosis (NARCOMS) 
patient registry. The random sample of 1,000 persons with MS 
received printed letters from NARCOMS staff, and the sample 
size was selected based on an expectation of 25% participation 
in the actual study, which was estimated by NARCOMS. Those 
who were interested in participating contacted the research team 
through Email or telephone, and members of the research team 
conducted a brief screening interview for inclusion. The inclusion 
criteria were: (a) age 18 years or older; (b) self‐reported diagnosis 
of MS; (c) member of the NARCOMS registry; and (d) willingness 
to complete the questionnaires and return the materials via the 
United States Postal Service (USPS). Of the 1,000 persons with 
MS recruited through NARCOMS, 316 made contact with the re‐
search team and 296 were screened for eligibility (Figure 1); one 
person declined to participate after the description of the study. 
The research team distributed study materials to 295 persons and 
F I G U R E  1   CONSORT diagram. PHI, 
Protected Health Information form
Did not complete (n = 20)
Declined to sign PHI (n = 8)
Other reasons (n = 12)
Declined to complete testing (n = 1)
Did not return materials (n = 11)
Assessed for eligibility (n = 296)
Enrolled (n = 295)
Contacted us (n = 316)
Recruited (n = 1,000)
Completed (n = 275)
Excluded (n = 1)
Declined to participate (n = 1)
Unable to reach after initial contact (n = 15)
Not interested (n = 5)
Other (n = 2)
Unknown (n = 3)
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284 individuals returned study materials to the research team. Of 
those who returned materials, nine declined to participate and 11 
persons did not return packets for unknown reasons. The final 
sample consisted of 275 persons with MS.
2.2 | Restless legs syndrome
2.2.1 | Diagnosis
The diagnosis of RLS was based on the Cambridge‐Hopkins Restless 
Legs Syndrome Questionnaire (CH‐RLSq), which has demonstrated 
validity and sensitivity for diagnosing RLS via a survey (Allen, Burchell, 
Macdonald, Hening, & Earley, 2009). The CH‐RLSq requires that par‐
ticipants fulfill the five criteria for a positive diagnosis of RLS and fur‐
ther includes items to help exclude common mimics of RLS (i.e., leg 
cramps and positional discomfort). These items consisted of five yes 
or no questions, two questions assessing when symptoms occur (i.e., 
at rest or when active, as well as the time of day) and one question for 
assessing if a single occurrence of movement relieves the symptoms 
(i.e., usually relieves, does not usually relieve, or don't know). Items 
were reviewed by a researcher and scored as positive for RLS (i.e., 
the MS + RLS group) if responses were consistent with the aforemen‐
tioned RLS diagnostic criteria or as negative for RLS (i.e. the MS group) 
if any item was inconsistent with RLS diagnostic criteria.
2.2.2 | Symptom severity
The severity of symptoms of the restless legs syndrome was measured 
using the International Restless Legs Syndrome Study Group (IRLS) 
Scale. The IRLS is a validated 10‐question survey that provides a global 
score commonly used to assess the overall severity of symptoms over 
the previous 7 days (Walters et al., 2003). Items were rated on a scale 
ranging from 0 to 4 and individual item scores were summed for a meas‐
ure of overall symptom severity ranging from 0 to 40. IRLS scores were 
further categorized into no symptoms (score of 0), mild (score 1–10), 
moderate (score 11–20), severe (score 21–30) and very severe (score 
31–40) (Walters et al., 2003). The IRLS has demonstrated validity, reli‐
ability and responsiveness in clinical trial settings (Abetz et al., 2006).
2.3 | Health‐related quality of life
The Multiple Sclerosis Impact Scale (MSIS‐29) provides a disease‐
specific measure of HRQOL (Hobart, Lamping, Fitzpatrick, Riazi, & 
Thompson, 2001). The MSIS‐29 measures physical and psychological 
aspects of HRQOL using 29 separate items rated on a five‐point Likert 
scale from 1 (not at all) to 5 (extremely) with regard to the past 4 weeks. 
Respective items were utilized to generate subscale scores for the 
physical and psychological domains of HRQOL. The physical domain 
was scored by summing the scores for items 1–20, subtracting 20, di‐
viding the difference by 80, and then multiplying the result by 100. 
The psychological domain was scored by summing the scores for items 
21 to 29, subtracting nine, dividing the difference by 36 and then mul‐
tiplying by 100. Higher scores on both subscales represent a greater 
impact of MS on HRQOL during the previous 2 weeks. Reliability and 
validity of the MSIS‐29 have been demonstrated in subjects with MS 
(Learmonth, Hubbard, Mcauley, & Motl, 2014).
2.4 | Demographics and clinical characteristics
Participants completed a demographic and clinical characteristics 
questionnaire for information regarding age, sex, race, MS subtype 
and disease duration. Participants further completed the Patient 
Determined Disease Steps (PDDS), a single item measure of self‐re‐
ported disability status (Hohol, Orav, & Weiner, 1995, 1999). PDDS 
scores ranged between 0 (normal) and 8 (bedridden), and the scores 
have demonstrated evidence for validity and strong correlations 
with the Expanded Disability Status Scale (EDSS), pyramidal and 
cerebellar functional scores and walking ability in persons with MS 
(Learmonth et al., 2013).
2.5 | Sleep quality
Subjective sleep quality was assessed with the Pittsburgh Sleep 
Quality Index (PSQI) (Buysse, Reynolds, Monk, Berman, & Kupfer, 
1989). The PSQI consists of 19 items that measure the quality of 
one's sleep and sleep disturbances over the past month. The items 
include a number of factors associated with sleep quality, including 
subjective sleep quality, duration of sleep, sleep latency, habitual 
sleep efficiency (i.e., frequency and severity of sleep‐related prob‐
lems, including breathing difficulty, pain, urinary frequency), use of 
sleeping medications, and the impact of poor sleep on daily func‐
tioning. Components were scored from 0 (fairly good) to 3 (very bad) 
and component scores are summed for a global score ranging from 
0 to 21; higher scores reflect worse sleep quality. Of note, scores 
greater than 5 are indicative of severe difficulties in at least two do‐
mains or moderate difficulties in more than three areas and the PSQI 
has demonstrated evidence for validity and reliability in assessing 
sleep quality in the general population (Buysse et al., 1989).
2.6 | Fatigue symptoms
Perceived fatigue was measured using the Fatigue Severity Scale (FSS) 
(Krupp, Larocca, Muir‐Nash, & Steinberg, 1989). The FSS contains nine 
Likert‐scale items that assess fatigue symptoms during the past week, 
rated on a 7‐point scale ranging between 1 (strongly disagree) and 
7 (strongly agree). Items were averaged for an overall measure of a 
person's severity of fatigue that ranges between 1 and 7. Of note, FSS 
scores of 4 (or total scores of 36) or above indicate severe MS‐related 
fatigue (Andreasen, Stenager, & Dalgas, 2011). There is evidence for 
the internal consistency, test–retest reliability, validity and precision 
of FSS scores as a measure of fatigue (Krupp et al., 1989).
2.7 | Anxiety and depression symptoms
The Hospital Anxiety and Depression Scale (HADS) contains 14 items 
that measure perceived symptoms of depression and anxiety over the 
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past 4 weeks (Zigmond & Snaith, 1983). Items were individually rated 
on a 4‐point scale ranging from 0 (most of the time) to 3 (not at all). A 
subset of seven items were reverse‐scored per subscale and summed 
into a subscale score for symptoms of depression (HADS‐D) or symp‐
toms of anxiety (HADS‐A) that ranged from 0 to 21; higher scores re‐
flected a greater frequency of depressive and anxiety symptoms. Of 
note, a cut‐point score of 7 has been identified for depression and anx‐
iety screening and a score of 11 suggests major depression and gen‐
eralized anxiety disorder in individuals with MS (Marrie et al., 2018). 
Additionally, the HADS has demonstrated evidence for the reliability 
and validity of these scores in people with MS (Marrie et al., 2018).
2.8 | Procedures
This study was approved by the university's Institutional Review 
Board and all participants provided written informed consent. After 
initial telephone contact and screening, all participants who verbally 
volunteered were mailed a packet containing the informed‐consent 
document, questionnaire battery, and a prestamped and pread‐
dressed envelope for return service through the USPS. The par‐
ticipants were instructed to complete the battery of questionnaires 
over a 7‐day period. After completing the questionnaires, partici‐
pants returned a signed copy of the informed consent along with the 
study materials through the USPS. All participants received $10 for 
voluntary participation.
2.9 | Statistical analysis
All statistical analyses were conducted using SPSS version 24 
and descriptive data are presented as mean scores along with the 
standard deviations (SDs), unless otherwise specified. We examined 
skewness and kurtosis estimates and frequency distributions for 
establishing normality of the variables; the skewness and kurtosis 
estimates along with inspection of frequency distributions did not 
identify problems with normality for any of the main study variables 
(i.e., age, sex, race, MS type, disease duration, PDDS, IRLS, MSIS, 
PSQI, FSS and HADS). The differences in outcome measures be‐
tween groups (MS + RLS vs. MS) were therefore determined using 
an independent samples t test for continuous variables, the Mann–
Whitney U‐test for categorical variables and the chi‐squared test 
for nominal variables. Cohen's d was utilized to estimate the mag‐
nitude of difference between groups and effect sizes of 0.2, 0.5 
and 0.8 were interpreted as small, moderate and large, respectively 
(Cohen, 1988). Within the MS + RLS group, the associations among 
RLS severity, physical and mental components of HRQOL and MS‐
related consequences (i.e., disability status, sleep quality, fatigue, 
depression and anxiety) were examined by means of Pearson prod‐
uct (r) correlation coefficients; values of 0.1, 0.3 and 0.5 were in‐
terpreted as small, moderate and large, respectively (Cohen, 1988).
We evaluated the relationship between RLS diagnosis and phys‐
ical and psychological HRQOL scores using multivariate linear re‐
gressions with forward stepwise selection (α = 0.05). We regressed 
CH‐RLSq on each domain of HRQOL (i.e., physical and psychological) 
in Step 1, and CH‐RLSq plus variables that were significantly differ‐
ent between groups (i.e. MS + RLS vs. MS) with the HRQOL domains 
in Step 2. We examined the change in the standardized beta‐coef‐
ficient for CH‐RLSq and the domain of HRQOL between Steps 1 
and 2 for judging the variables that may be intermediary factors in 
the associations within the total sample of participants. Within the 
MS + RLS group, we examined potential intermediary variables in 
the relationship between RLS severity and physical and psychologi‐
cal HRQOL scores using multivariate linear regressions with forward 
stepwise selection (α = 0.05). We regressed the total IRLS score on 
each domain of HRQOL in Step 1, and RLS severity plus variables 
that were significantly associated with the HRQOL domain in Step 
2. We examined the change in the standardized beta‐coefficient for 
IRLS and the domain of HRQOL between Steps 1 and 2 for judging 
the variables that may be intermediary factors in the associations 
within those with MS + RLS. A p‐value of less than 0.05 was adopted 
for determining statistical significance with all inferential analyses.
3  | RESULTS
3.1 | Overall sample characteristics
Demographic and clinical characteristics for the overall sample of par‐
ticipants (n = 275) are presented in Table 1. The sample was largely fe‐
male (81%) and Caucasian (94.9%), with a mean age of 60 ± 10 years. 
Most participants had RRMS (65.6%) with moderate disability (median 
[interquartile range] PDDS score: 3.0 [5.0]), an average disease dura‐
tion of 20 ± 9.7 years, and most participants were using an MS‐spe‐
cific disease‐modifying therapy (DMT; 84.3%). The sample reported 
scores consistent with moderate‐to‐severe sleep disturbances (PSQI 
global score, 7.2 ± 3.6) and severe MS‐related fatigue (FSS: 4.7 ± 1.8), 
based on cut‐off scores of greater than 5 (Buysse et al., 1989) and 
greater than 4 (Andreasen et al., 2011) respectively.
3.1.1 | Restless legs syndrome in multiple sclerosis
Demographic and clinical characteristics of subsamples of 
MS + RLS (n = 74) and MS only (n = 201) are presented in Table 1. 
Approximately 27% of our sample fit the criteria for a positive di‐
agnosis of RLS based on the CH‐RLSq diagnostic questionnaire. 
Within the MS + RLS group, nine (12.2%) individuals reported 
no symptoms, 26 (35.1%) mild symptoms, 28 (37.8%) moderate 
symptoms, 10 (13.5%) severe symptoms, and one (1.4%) reported 
very severe symptoms of RLS. Of note, 20 (27%) participants with 
MS + RLS were taking medications that can reduce symptoms of 
RLS and 14 (18.9%) were taking medications that can exacerbate 
symptoms of RLS (Buchfuhrer, 2012; Restless Legs Syndrome 
Foundation, 2018). The two groups (i.e., MS + RLS and MS) were 
not significantly different in age, sex, race, MS type, disease dura‐
tion, self‐reported clinical disability status, number of participants 
on DMTs, sleep quality or depression symptoms.
The MS + RLS group reported significantly worse HRQOL in both 
domains (MSIS‐physical, p = 0.020; MSIS‐psychological, p = 0.007). The 
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MS + RLS group reported significantly greater perceived fatigue (FSS, 
p = 0.007) and anxiety symptoms (HADS‐A, p = 0.042) than the MS‐only 
group. Additionally, the MS + RLS group had a positive screening for anx‐
iety and depression based on a cut‐off score of 7 (Marrie et al., 2018). 
The difference between groups was small for the physical (d = 0.32) and 
psychological (d = 0.35) domains of HRQOL, perceived fatigue (d = 0.40), 
depression symptoms (d = 0.21) and anxiety symptoms (d = 0.25).
3.2 | Correlation analysis
The bivariate correlations among RLS severity, HRQOL, clini‐
cal disability status, sleep quality, fatigue, depression and anxiety 
in the MS + RLS group are presented in Table 2. RLS severity was 
significantly associated with physical (r = 0.43) and psychological 
(r = 0.46) HRQOL, sleep quality (r = 0.38), perceived fatigue (r = 0.28) 
and symptoms of depression (r = 0.38) and anxiety (r = 0.28). The 
physical domain of HRQOL was significantly associated with clinical 
disability status (r = 0.74), sleep quality (r = 0.33), fatigue (r = 0.68) 
and depression (r = 0.60); the psychological domain of HRQOL was 
significantly associated with sleep quality (r = 0.56), fatigue (r = 0.47), 
depression (r = 0.78) and anxiety (r = 0.74).
3.3 | Linear regression analysis
The summary of linear regression analyses for evaluating the re‐
lationship between RLS diagnosis and HRQOL in the total sample 




(N = 275) MS + RLS (n = 74) MS (n = 201) p‐value d
Age, years 59.7 ± 10.1 59.4 ± 9.9 59.9 ± 10.2 0.748 —
Sex, n (%) 223 (81.1%) F /52 
(18.9%) M
60 (81.1%) F /14 (18.9%) M 163 (81.1%) F /38 
(18.9%) M
0.998a —
Race, n (%)    0.422a —
American Indian 1 (0.4%) 0 (0.0%) 1 (0.5%) — —
Black/African American 4 (1.5%) 0 (0.0%) 4 (2.0%) — —
Caucasian 261 (94.9%) 73 (98.6%) 188 (93.4%) — —
Latino/Latina 5 (1.8%) 0 (0.0%) 5 (0.3%) — —
Other 3 (1.1%) 1 (1.4%) 2 (1.0%) — —
MS type, n (%)    0.731a —
RRMS 181 (65.8%) 48 (64.9%) 133 (66.2%) — —
SPMS 58 (21.1%) 17 (23.0%) 41 (20.4%) — —
PPMS 33 (12.0%) 9 (12.2%) 24 (11.9%) — —
Benign 3 (1.1%) 0 (0.0%) 3 (1.5%) — —
Disease duration, years 20.4 ± 9.7 20.0 ± 9.7 20.5 ± 9.7 0.686 —
MS DMT, n (%) 231 (84.3%) 53 (71.6%) 149 (74.1%) 0.676a —
PDDS, median (IQR) 3.0 (5) 3.5 (3) 3.0 (5) 0.291b —
IRLS 7.6 ± 8.0 11.4 ± 7.6 6.2 ± 7.7 0.000 0.680
RLS modifying Rx 69 (25.1%) 20 (27.0%) 49 (24.4%) 0.653a —
RLS exacerbating Rx 39 (14.2%) 14 (18.9%) 25 (12.4%) 0.172a —
MSIS‐physical 35.0 ± 25.0 40.7 ± 24.6 32.8 ± 24.8 0.020 0.319
MSIS‐psychological 25.3 ± 19.1 30.4 ± 22.7 23.4 ± 17.3 0.007 0.347
PSQI 6.9 ± 3.4 7.3 ± 3.8 6.7 ± 3.2 0.172 0.171
FSS 4.7 ± 1.8 5.2 ± 1.7 4.5 ± 1.8 0.007 0.400
HADS‐D 6.9 ± 2.8 7.3 ± 3.1 6.7 ± 2.7 0.115 0.206
HADS‐A 6.7 ± 2.7 7.2 ± 3.1 6.5 ± 2.5 0.042 0.249
Data are presented as mean ± standard deviation unless otherwise specified. Bolded values are indicative of significant differences between groups.
Abbreviations: MS, multiple sclerosis; RLS, restless legs syndrome; RRMS, relapsing‐remitting MS; SPMS, secondary progressive MS; PPMS, primary 
progressive MS; PDDS, Patient Determined Disease Status; IQR, interquartile range; IRLS, International Restless Legs Syndrome Study Group Scale; 
MSIS, Multiple Sclerosis Impact Scale; PSQI, Pittsburgh Sleep Quality Index; FSS, Fatigue Severity Scale; HADS‐D, Hospital Anxiety and Depression 
Scale‐Depression domain; HADS‐A, Hospital Anxiety and Depression Scale‐Anxiety domain.
aChi‐square analysis. 
bWilcoxon–Mann–Whitney test. 
6 of 9  |     CEDERBERG Et al.
(n = 275) is presented in Table 3. RLS diagnosis significantly pre‐
dicted the physical domain of HRQOL in Step 1 (F = 5.310, p = 0.022; 
R2 = 0.019), and this relationship was accounted for by FSS and 
HADS‐A in Step 2 (F = 29.564, p = 0.000; R change = 0.228). RLS di‐
agnosis significantly predicted the psychological domain of HRQOL 
in Step 1 (F = 7.362, p = 0.007; R2 = 0.026), and this relationship was 
accounted for by FSS and HADS‐A in Step 2 (F = 109.293, p = 0.000; 
R2 change = 0.522).
The summary of linear regression analyses for evaluating vari‐
ables that may be intermediary in the relationship between RLS se‐
verity and HRQOL in those with MS + RLS (n = 74) is presented in 
Table 4. RLS severity significantly predicted the physical domain of 
HRQOL in Step 1 (F = 16.259, p = 0.000; R2 = 0.184), and this rela‐
tionship was partially accounted for by FSS and HADS‐D in Step 2 
(F = 26.626, p = 0.000; R2 change = 0.423). RLS severity significantly 
predicted the psychological domain of HRQOL in Step 1 (F = 19.646, 
p = 0.000; R2 = 0.214), and this relationship was partially accounted 
for by FSS, HADS‐D and HADS‐A in Step 2 (F = 37.113, p = 0.000; 
R2 change = 0.596).
4  | DISCUSSION
This study provided a novel evaluation of the relationship between 
RLS severity and HRQOL, and identified potential intermediary vari‐
ables in this relationship for persons with MS and RLS. Persons with 
MS and RLS had reduced HRQOL in both the physical and psycho‐
logical domains. Consistent with previous research, persons with MS 
and RLS experienced more severe fatigue and a greater frequency 
of anxiety symptoms than those without RLS (Cederberg & Motl, 
2016; Giannaki et al., 2018). Among those with MS and RLS, RLS 
severity was moderately correlated with HRQOL, whereby greater 
RLS severity was associated with a greater impact of MS on both 
physical and psychological domains of HRQOL. The relationships 
between RLS severity and the domains of HRQOL were attenuated 
when accounting for fatigue, depression and/or anxiety, suggesting 
that these symptoms may be intermediary factors in the association 
between RLS severity and HRQOL.
Within this study of adults with MS, meeting the diagnostic cri‐
teria for RLS was associated with significantly worse physical and 
psychological HRQOL, fatigue, anxiety and depression, thereby 
suggesting that the presence of RLS in adults with MS may nega‐
tively impact HRQOL and associated outcomes. The presence of 
RLS significantly predicted the physical and psychological domains 
TA B L E  2   Summary of Pearson product bivariate correlations in adults with restless legs syndrome and multiple sclerosis (n = 74)
 IRLS MSIS‐Physical MSIS‐Psychological PDDS PSQI FSS HADS‐D
MSIS‐physical 0.429b —      
MSIS‐ psychological 0.463b 0.563b —     
PDDS 0.194 0.737b 0.075 —    
PSQI 0.382b 0.334b 0.561b 0.096 —   
FSS 0.277a 0.678b 0.474b 0.363b 0.409b —  
HADS‐D 0.375b 0.599b 0.776b 0.284a 0.443b 0.437b —
HADS‐A 0.278a 0.202 0.740b −0.168 0.383b 0.102 0.562b
Abbreviations: IRLS, International Restless Legs Syndrome Study Group Scale; MSIS, Multiple Sclerosis Impact Scale; PDDS, Patient Determined 
Disease Status; PSQI, Pittsburgh Sleep Quality Index; FSS, Fatigue Severity Scale; HADS‐D, Hospital Anxiety and Depression Scale‐Depression 
domain; HADS‐A, Hospital Anxiety and Depression Scale‐Anxiety domain.
ap < 0.05. 
bp < 0.01. 
TA B L E  3   Summary of linear regression analysis for restless legs 
syndrome diagnosis and other variables predicting the physical and 
psychological domains of health‐related quality of life in adults with 
multiple sclerosis (n = 275)
 B SE B β
MSIS‐physical
Step 1
CH‐RLSq 7.764 3.369 0.138a
Step 2
CH‐RLSq 3.036 3.019 0.054
FSS 6.684 0.756 0.476a
HADS‐A 0.482 0.494 0.052
R2	=	0.019	for	step	1;	∆R2 = 0.228 for step 2. ap < 0.05
MSIS‐psychological
Step 1
CH‐RLSq 6.975 2.571 0.162a
Step 2
CH‐RLSq 1.393 1.791 0.032
FSS 3.695 0.449 0.343a
HADS‐A 4.297 0.293 0.607a
R2	=	0.026	for	step	1;	∆R2 = 0.522 for step 2. ap < 0.05
Abbreviations: MSIS, Multiple Sclerosis Impact Scale; CH‐RLSq, 
Cambridge‐Hopkins Restless Legs Syndrome Questionnaire; FSS, 
Fatigue Severity Scale; HADS‐A, Hospital Anxiety and Depression 
Scale‐Anxiety domain.
ap < 0.05. 
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of HRQOL, yet our results suggest that the severity of fatigue and 
frequency of anxiety symptoms partially account for such relation‐
ships. This further suggests that fatigue and symptoms of anxiety 
may be important intermediaries in the relationship between RLS 
diagnosis and HRQOL in adults with MS.
Our results indicated that anxiety was significantly worse in 
adults with MS and RLS and that anxiety was positively associated 
with RLS severity and the psychological domain of HRQOL. To date, 
this is the first study to evaluate symptoms of anxiety in adults 
with MS and RLS. Anxiety is characterized by excessive worry that 
an individual finds difficult to control, which can cause significant 
problems in other areas of life (National Institute of Mental Health, 
2018). Results from the current study suggest that anxiety may be 
an important factor in the relationships among RLS, RLS severity 
and HRQOL; however, the pathological connection between RLS 
and anxiety is unclear. One potential explanation is that RLS shares 
similar characteristics with anxiety disorders, wherein the diag‐
nostic criteria for generalized anxiety disorder include symptoms 
of restlessness, fatigue, difficulty concentrating, irritability, muscle 
tension and sleep disturbance (Patriquin & Mathew, 2017). Thus, 
the unpredictable and uncontrollable nature of RLS symptoms may 
contribute to or exacerbate anxiety symptoms, which in turn impact 
HRQOL in adults with MS. More research is necessary to further 
evaluate the temporal relationship between RLS severity and anx‐
iety, as well as the impact of anxiety in persons with MS and RLS.
Results from the current study indicated that a reduced HRQOL 
in the physical domain was associated with worse RLS severity, 
greater self‐reported clinical disability, poorer sleep quality, greater 
fatigue severity and a higher frequency of depression. Similarly, 
reduced HRQOL in the psychological domain was associated with 
worse RLS severity, poorer sleep quality, greater fatigue and a greater 
frequency of depression and anxiety symptoms. These results are 
similar to previous literature that has demonstrated significant 
correlations between HRQOL and fatigue, poor sleep (Lobentanz 
et al., 2004; Amato et al., 2001, Boe Lunde et al., 2012; Tabrizi & 
Radfar, 2015; Kotterba et al., 2018), depression (Amato et al., 2001; 
Lobentanz et al., 2004) and anxiety (Fruehwald, Loeffler‐Stastka, 
Eher, Saletu, & Baumhackl, 2001) in persons with MS. Importantly, 
this is the first study to identify severity of RLS as an important 
correlate of HRQOL and this association may be accounted for by 
fatigue, depression and anxiety. These results build upon current 
literature that identifies depression and fatigue as strong predic‐
tors of HRQOL in persons with MS (Amato et al., 2001; Fruehwald 
et al., 2001; Lobentanz et al., 2004; Nourbakhsh, Julian, & Waubant, 
2016). Future research should consider other possible factors that 
may mediate the relationship between the severity of RLS symptoms 
and HRQOL in persons with MS.
5  | LIMITATIONS
There are important limitations to consider when interpreting our 
results. The cross‐sectional design of this study precludes any 
inferences of causality or temporality. The response rate from 
the NARCOMS registry was low (i.e., 31%) and further reduced 
(27%) based on valid questionnaires. Thus, selection bias may have 
played a role in our results. As this was a mail‐based protocol, all 
measures are self‐report in nature. The lack of an interview for RLS 
diagnosis may have led to false negative or false positive diagnoses 
on the CH‐RLSq. However, the RLS diagnostic questionnaire (i.e., 
CH‐RLSq) has been validated for diagnosing RLS, with considera‐
tion of certain RLS mimics, in the general population (Allen et al., 
2009). We did not include criteria for a minimum time since di‐
agnosis. Some prescription medications for MS present another 
limitation to assessing RLS symptom severity in this population, as 
a number of prescriptions for symptoms and consequences of MS 
can be used to treat symptoms of RLS (e.g., pramipexole, gabapen‐
tin and rotigotine; Restless Legs Syndrome Foundation, 2018) or 
may exacerbate symptoms of RLS (e.g., antidepressants, first‐gen‐
eration antihistamines; Buchfuhrer, 2012); 25.1% (n = 69) of our 
sample with MS and RLS were taking a medication that could re‐
duce RLS severity and 14.2% (n = 39) were taking medications that 
could exacerbate RLS severity. This paper included only a single 
TA B L E  4   Summary of linear regression analysis for restless legs 
syndrome severity and other variables predicting the physical and 
psychological domains of health‐related quality of life in adults with 
restless legs syndrome and multiple sclerosis (n = 74)
 B SE B β
MSIS‐physical
Step 1
IRLS 1.393 0.345 0.429a
Step 2
IRLS 0.641 0.275 0.198a
PSQI −0.647 0.548 −0.105
FSS 7.508 1.271 0.515a
HADS‐D 2.686 0.704 0.343a
R2	=	0.184	for	step	1;	∆R2 = 0.423 for step 2. ap < 0.05
MSIS‐psychological
Step 1
IRLS 1.383 0.312 0.463a
Step 2
IRLS 0.338 0.178 0.113
PSQI 0.512 0.363 0.090
FSS 2.809 0.852 0.209a
HADS‐D 2.488 0.532 0.345a
HADS‐A 3.410 0.499 0.461a
R2	=	0.214	for	step	1;	∆R2 = 0.594 for step 2. ap < 0.05
Abbreviations: MSIS, Multiple Sclerosis Impact Scale; IRLS, International 
Restless Legs Syndrome Study Group Scale; PSQI, Pittsburgh Sleep 
Quality Index; FSS, Fatigue Severity Scale; HADS‐D, Hospital Anxiety 
and Depression Scale‐Depression domain; HADS‐A, Hospital Anxiety 
and Depression Scale‐Anxiety domain.
ap < 0.05. 
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measure for the evaluation of sleep, but it did not include a meas‐
ure for assessing daytime sleepiness (e.g., the Epworth Sleepiness 
Scale). This is a limitation as daytime sleepiness is a common cor‐
relate of RLS that may impact HRQOL. Our sample consisted pri‐
marily of persons with RRMS (65.8%), suggesting that our sample 
may not be fully representative of the MS population, and we fur‐
ther note that some subjects may be unaware of a transition from 
RRMS to secondary progressive MS (SPMS). Additionally, this high 
prevalence of individuals with RRMS may not be representative of 
the MS + RLS population as prior literature suggests that RLS may 
be more prevalent in those with PPMS and those with greater lev‐
els of disability (Manconi et al., 2007, 2008). However, we included 
a large, random sample of individuals with MS that included all 
phenotypes of MS and our sample was representative of US peak 
prevalence (i.e., 55–64 years) for age and sex (Wallin et al., 2019), 
disease duration and MS type (Multiple Sclerosis International 
Foundation, 2013).
6  | CONCLUSIONS
This study sheds new light on the relationships among RLS sever‐
ity, MS symptomology and physical and psychological domains of 
HRQOL. Persons with MS and RLS experience reduced HRQOL in 
both physical and psychological domains, worse fatigue and more 
frequent symptoms of depression and anxiety. Greater severity of 
RLS was associated with both physical and psychological domains of 
HRQOL, which was seemingly accounted for by fatigue, depression 
and anxiety. These results identify a possible pathway for mitigating 
reductions in HRQOL through the reduction of RLS and other MS 
symptoms (e.g., fatigue and anxiety). The identification of intermedi‐
ary factors in the relationship between RLS and QOL in MS provides 
valuable information that could be utilized to improve symptomatic 
treatment and modulate treatment over time, consequently improv‐
ing HRQOL, in persons with MS and RLS. Future research should 
further examine the role of anxiety in persons with MS and RLS, as 
well as identify correlates and factors that may mediate the relation‐
ship between RLS and HRQOL, as early identification and treatment 
of modifiable factors, such as fatigue, depression and anxiety, may 
improve quality of life in people with MS and RLS.
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